Think of HYPORT. Let’s go slowly.

01.06.2025 11:46 — 👍 1    🔁 0    💬 0    📌 0

What could be better than 5 days in Verona in October, learning about prostate cancer? Comprehensive multidisciplinary programme aimed at oncologists, urologists, radiologists and anyone else involved in treated prostate cancer. Spread the word!

21.05.2025 16:12 — 👍 9    🔁 7    💬 1    📌 0

Important (and puzzling) results from the Skagen Trial 1:
Moderate hypofractionation for high-risk (node-positive) breast cancer patients does not increase arm lymphoedema - but is *does* seem to increase the breast-cancer related mortality 😲
#ESTRO25 #radonc

03.05.2025 09:02 — 👍 1    🔁 1    💬 1    📌 0

Comment on Wu et al’s article on toxicity in patients receiving radiotherapy for ultracentral stage I non-small cell lung cancer We reviewed the article by Wu et al. with great interest [1]. This secondary analysis of the LUSTRE randomized trial focused on toxicity in patients receiving radiotherapy for ultracentral (UC) lesion...

The optimal treatment of ultracentral lung tumors is still a matter of discussion in the lung Radiation Oncology community.

Along with Dr Shankar Siva and Dr Drew Moghanaki, we discussed the notion of "acceptable toxicity" for ultracentral SBRT.

Keep it 60 Gy in 15 fractions !

26.02.2025 17:14 — 👍 3    🔁 1    💬 0    📌 0